NASDAQ: APTO | Healthcare / Biotechnology / Canada |
0.8350 | -0.0019 | -0.23% | Vol 115.15K | 1Y Perf -66.79% |
Aug 11th, 2022 15:59 DELAYED |
BID | 0.8150 | ASK | 0.8366 | ||
Open | 0.8200 | Previous Close | 0.8369 | ||
Pre-Market | - | After-Market | 0.84 | ||
- - | 0.00 0.19% |
Target Price | 8.50 | Analyst Rating | Strong Buy 1.00 | |
Potential % | 917.96 | Finscreener Ranking | — - | |
Insiders Trans % 3/6/12 mo. | 100/100/100 | Value Ranking | — - | |
Insiders Value % 3/6/12 mo. | 100/100/100 | Growth Ranking | — - | |
Insiders Shares Cnt. % 3/6/12 mo. | 100/100/100 | Income Ranking | — - | |
Price Range Ratio 52W % | 5.11 | Earnings Rating | Strong Buy | |
Market Cap | 77.06M | Earnings Date | 2nd Aug 2022 | |
Alpha | 0.00 | Standard Deviation | 0.24 | |
Beta | 1.60 |
Today's Price Range 0.82000.8774 | 52W Range 0.71183.13 | 5 Year PE Ratio Range -7.40-2.10 |
Summary:
Neutral
Technical Indicators: | Neutral |
Moving Averages: | Neutral |
Performance | |||
---|---|---|---|
1 Week | -3.61% | ||
1 Month | -1.57% | ||
3 Months | -17.33% | ||
6 Months | -29.83% | ||
1 Year | -66.79% | ||
3 Years | -69.41% | ||
5 Years | -42.41% | ||
10 Years | - |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | -52.36 | |||
ROE last 12 Months | -71.90 | |||
ROA (5Y Avg) | -31.78 | |||
ROA last 12 Months | -66.83 | |||
ROC (5Y Avg) | -100.84 | |||
ROC last 12 Months | -68.91 | |||
Return on invested Capital Q | -16.36 | |||
Return on invested Capital Y | -29.66 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | - |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
-1.30 | ||||
1.17 | ||||
- | ||||
- | ||||
-2.30 | ||||
-0.62 | ||||
1.22 | ||||
0.71 | ||||
6.96M | ||||
Forward PE | -1.44 | |||
PEG | - |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
9.50 | ||||
9.80 | ||||
0.00 | ||||
0.01 | ||||
- | ||||
Leverage Ratio | 1.10 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
- |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
0.00 | ||||
0.00 | ||||
- | ||||
- |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
- | ||||
- | ||||
- | ||||
- | ||||
Payout ratio | - |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q02 2022 | -0.13 | -0.11 | 15.38 |
Q01 2022 | -0.15 | -0.12 | 20.00 |
Q04 2021 | -0.18 | -0.27 | -50.00 |
Q03 2021 | -0.17 | -0.13 | 23.53 |
Q02 2021 | -0.18 | -0.15 | 16.67 |
Q01 2021 | -0.17 | -0.18 | -5.88 |
Q04 2020 | -0.16 | -0.17 | -6.25 |
Q03 2020 | -0.18 | -0.15 | 16.67 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
6/2022 QR | -0.13 | 18.75 | Positive |
9/2022 QR | -0.14 | 17.65 | Positive |
12/2022 FY | -0.57 | 17.39 | Positive |
12/2023 FY | -0.60 | 14.29 | Positive |
Next Report Date | - |
Estimated EPS Next Report | -0.13 |
Estimates Count | 3 |
EPS Growth Next 5 Years % | - |
Volume Overview | |
---|---|
Volume | 115.15K |
Shares Outstanding | 92.28K |
Shares Float | 90.98M |
Trades Count | 327 |
Dollar Volume | 96.80K |
Avg. Volume | 260.08K |
Avg. Weekly Volume | 348.99K |
Avg. Monthly Volume | 185.08K |
Avg. Quarterly Volume | 246.18K |
Aptose Biosciences Inc. (NASDAQ: APTO) stock closed at 0.835 per share at the end of the most recent trading day (a -0.23% change compared to the prior day closing price) with a volume of 115.15K shares and market capitalization of 77.06M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 31 people. Aptose Biosciences Inc. CEO is William G. Rice.
The one-year performance of Aptose Biosciences Inc. stock is -66.79%, while year-to-date (YTD) performance is -38.15%. APTO stock has a five-year performance of -42.41%. Its 52-week range is between 0.7118 and 3.125, which gives APTO stock a 52-week price range ratio of 5.11%
Aptose Biosciences Inc. currently has a PE ratio of -1.30, a price-to-book (PB) ratio of 1.17, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -66.83%, a ROC of -68.91% and a ROE of -71.90%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Aptose Biosciences Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.13 for the next earnings report. Aptose Biosciences Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Aptose Biosciences Inc. is Strong Buy (1), with a target price of $8.5, which is +917.96% compared to the current price. The earnings rating for Aptose Biosciences Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Aptose Biosciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Aptose Biosciences Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 14.52, ATR14 : 0.06, CCI20 : 63.83, Chaikin Money Flow : -0.17, MACD : 0.00, Money Flow Index : 46.54, ROC : 7.43, RSI : 40.46, STOCH (14,3) : 60.09, STOCH RSI : 0.89, UO : 54.48, Williams %R : -39.91), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Aptose Biosciences Inc. in the last 12-months were: Denis R. Burger (Buy at a value of $14 490), Denis R. Burger (Option Excercise at a value of $11 051), Erich M. Platzer (Buy at a value of $454 240), William G. Rice (Buy at a value of $69 645)
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Strong Buy | Strong Buy | Strong Buy |
Aptose Biosciences Inc is a biotechnology company. It develops targeted medicines and personalized therapies for the precision treatment of life-threatening cancers such as acute myeloid leukemia, myelodysplastic syndromes and other hematologic malignancies and also therapies for Oncology. The firm has CG-806, APTO-253 drugs in preclinical development stage pipeline.
CEO: William G. Rice
Telephone: +1 650 718-5028
Address: 251 Consumers Road, Toronto M2J 4R3, ON, CA
Number of employees: 31
Tue, 10 May 2022 13:40 GMT Analysts Offer Insights on Healthcare Companies: Aptose Biosciences (APTO) and Applied Molecular Transport (AMTI)
- TipRanks. All rights reserved.Thu, 24 Mar 2022 10:40 GMT Aptose Biosciences (APTO) Gets a Buy Rating from RBC Capital
- TipRanks. All rights reserved.Wed, 23 Mar 2022 20:35 GMT Aptose Biosciences (APTO) Gets a Buy Rating from Alliance Global Partners
- TipRanks. All rights reserved.Wed, 23 Mar 2022 12:25 GMT Analysts Top Healthcare Picks: Aptose Biosciences (APTO), Frequency Therapeutics (FREQ)
- TipRanks. All rights reserved.Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. CBOE EDGX Top real-time data for Premium users, NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Technology and data provided by TeleTrader. Conditions of Use. The regulations of the respective stock are to be observed. Copyright © 2022. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer. The Cryptocurrency Market real-time data provided by Cryptocompare.com
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.